Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?

Literature DB >> 12212783

Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?

D Larry Sparks¹, Donald J Connor, Patrick Browne, Marwan N Sabbagh.

Abstract

Elevated circulating cholesterol can have profound effects on the health of an individual. Such excess cholesterol can promote coronary artery disease, production and accumulation of beta-amyloid in the brain, and possibly Alzheimer's disease (AD). In a clinical trial evaluating the benefit of a cholesterol-lowering drug in the treatment of AD, mean cholesterol levels at baseline among individuals participating in the trial were found to be relatively high. Based on this observation we suggest that cholesterol levels should be actively monitored in the elderly, as many individuals with AD are over 65 years of age and therefore excluded by currently accepted guidelines.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2002 PMID： 12212783 DOI： 10.1007/s12031-002-0035-1

Source DB: PubMed Journal: J Mol Neurosci ISSN： 0895-8696 Impact factor: 3.444

28 in total

1. Intraneuronal beta-amyloid immunoreactivity in the CNS.

Authors: D L Sparks
Journal: Neurobiol Aging Date: 1996 Mar-Apr Impact factor: 4.673

2. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort.

Authors: D W Desmond; T K Tatemichi; M Paik; Y Stern
Journal: Arch Neurol Date: 1993-02

3. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. American College of Physicians. Part 1.

Authors:
Journal: Ann Intern Med Date: 1996-03-01 Impact factor: 25.391

4. 15-year longitudinal study of blood pressure and dementia.

Authors: I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg
Journal: Lancet Date: 1996-04-27 Impact factor: 79.321

5. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.

Authors: I L Notkola; R Sulkava; J Pekkanen; T Erkinjuntti; C Ehnholm; P Kivinen; J Tuomilehto; A Nissinen
Journal: Neuroepidemiology Date: 1998 Impact factor: 3.282

6. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.

Authors: D L Sparks; Y M Kuo; A Roher; T Martin; R J Lukas
Journal: Ann N Y Acad Sci Date: 2000-04 Impact factor: 5.691

1. A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT).

Authors: D Larry Sparks; Jean Lopez; Don Connor; Marwan Sabbagh; Jim Seward; Patrick Browne
Journal: J Mol Neurosci Date: 2003 Impact factor: 3.444

1 in total

Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?

1. Intraneuronal beta-amyloid immunoreactivity in the CNS.

2. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort.

3. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. American College of Physicians. Part 1.

4. 15-year longitudinal study of blood pressure and dementia.

5. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.

6. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.

7. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

8. Statins and the risk of dementia.

9. Epidemiology of coronary heart disease: the Framingham study.

10. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.

1. A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT).